sabizabulin VERU-111 cas: 1332881-26-1

CAS NO: 1332881-26-1
CBNumber: CB05569748
english name: sabizabulin
中文名称: VERU-111
MF: C21H19N3O4
MW: 377.39
CAS: 1332881-26-1
Description Review
Description
VERU-111, also known as Sabizabulin, is a chemical that is gaining attention in the fields of antiviral medicine and cancer. With its distinct method of action, this chemical is receiving interest in the scientific community for its prospective uses.



Keywords for Google's Most Popular searches "Sabizabulin oncology research" , "VERU-111 COVID-19 trials" , "1332881-26-1 microtubule disruption" , "Anticancer potential of Sabizabulin" , "Clinical studies on VERU-111" , "Microtubule agents in viral infections" .

Similar Products from Competitors
Sabizabulin is a member of the same pharmacological family as other well-established microtubule-targeting medicines used to treat a variety of malignancies, such as paclitaxel and docetaxel.

Health Advantages and Risks
The capacity of Sabizabulin to break microtubules in cancer cells provides a promising strategy in slowing the growth of tumor cells, which might possibly assist in the treatment of specific forms of cancer due to its potential to treat cancer.

Treatment for COVID-19: Sabizabulin's distinct impact on microtubules may hinder the virus's ability to replicate, providing a possible treatment route.

Product Design Mechanism
Sabizabulin targets microtubules, which are essential elements in both intracellular transport and cell division, in order to achieve its mechanism of action. Impeding the intracellular transport of viruses such as SARS-CoV-2, this disruption causes the demise of swiftly dividing cancer cells. Safety and Adverse Reactions
While Sabizabulin's safety profile is still being studied in clinical studies, common worries about microtubule inhibitors include how they might affect cell division and how harmful they might be to regular cells that divide quickly.

Contraindications and Dosage
Clinical studies are being conducted to provide precise dose parameters for Sabizabulin. Its usage must be closely controlled, especially in those who have pre-existing health issues that might be aggravated by microtubule inhibition.


In summary
Sabizabulin (VERU-111) is a leading advancement in the field of oncology and antiviral therapy, distinguished by its innovative nature. The fact that it can fight both cancer and viral diseases like COVID-19 makes it a substance that doctors are very interested in.

sabizabulin VERU-111 cas: 1332881-26-1

"People Also Ask"

Part Q: What sets Sabizabulin different from the conventional chemotherapy drugs?
Since Sabizabulin exclusively targets microtubules, it provides a potentially more tailored approach to the treatment of cancer, in contrast to other standard chemotherapy drugs that have a wide mode of action.

Q: How are Sabizabulin clinical studies going?
A: The medical world is excitedly awaiting the results of clinical studies being conducted on Sabizabulin to assess its safety and effectiveness in treating COVID-19 and specific cancer types.



  • Sabizabulin cancer treatment,
  • VERU-111 COVID-19 research,
  • Microtubule-targeting agents,
  • Sabizabulin clinical trials,
  • Antiviral properties of Sabizabulin,
  • VERU-111 mechanism of action,
  • Innovative cancer therapies,
  • COVID-19 treatment breakthroughs,
  • Microtubule disruption in pharmacology,
  • Sabizabulin pharmacological profile.
    • Sabizabulin cancer treatment",
    • "VERU-111 COVID-19 research",
    • "Microtubule-targeting agents in oncology",
    • "Sabizabulin clinical trials",
    • "Mechanism of action of VERU-111",
    • "Antiviral properties of sabizabulin",
    • "Emerging therapies for COVID-19".
  •  
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code